PubMed Triage Digest — 2026-08-03

Run: Attempt 1 of 3 · 20260803T090000Z
Date window: 2026-08-02 → 2026-08-03 (CRDT)
Total articles included: 25 (8 HIGH ≥9, 9 HIGH 7–8, 6 MEDIUM score 6, 2 MEDIUM score 5, 1 LOW)

⭐ TOP FINDS — Score 9

🔵 T7 · Cardiovascular-Metabolic (GLP-1/SGLT2)

[NEAR_TERM_IMPLEMENTABLE] PMID 42543082 — Guideline on treatment intensification with injectable therapies beyond GLP-1 RA based therapies in type 2 diabetes
Luo Y, Xia J, Yao X et al. | Diabetes Res Clin Pract | 2026-08-02
DOI: 10.1016/j.diabres.2026.113474
Score: 9/10 (novelty 2, design 2, population 2, maturity 3)

GRADE guideline from a 22-member Asia-Pacific panel synthesizes 8 RCTs via GRADE framework. Panel conditionally recommends switching to dual GIP/GLP-1 RA (tirzepatide class) for glycemic and weight benefits, or to fixed-ratio combination (FRC) for glycemic-focused intensification, over simply switching to another GLP-1 RA. Adding basal insulin with structured education is an alternative.
Why it matters: Directly actionable for prescribers managing T2DM progression beyond GLP-1 RA monotherapy. Covers the exact sequencing question with multinational RCT synthesis.

[HIGH] PMID 42543031 — Sepsis risk in patients with COPD and type 2 diabetes mellitus: influence of emerging antihyperglycemic therapies
Kuo KC, Chen CH, Wu TJ et al. | Expert Rev Respir Med | 2026-08-02
DOI: 10.1080/17476348.2026.2713233
Score: 9/10 (novelty 3, design 2, population 2, maturity 2)

Large real-world study: 45,491 propensity-matched pairs from TriNetX global database. GLP-1RAs versus SGLT2 inhibitors in COPD+T2DM — GLP-1RAs showed significantly lower sepsis (HR 0.83), severe sepsis (HR 0.84), and all-cause mortality (HR 0.64). New-user active-comparator design.
Why it matters: Novel finding of GLP-1RA advantage over SGLT2i for infection outcomes in a very common dual-comorbidity population; adds to pleiotropic benefits beyond glycemia.

[HIGH] PMID 42542611 — GSK3B variations influence renoprotective responses to dapagliflozin in diabetic kidney disease
Song J, Xu Y, Zhuang Y et al. | iScience | 2026-07-23 (PMC open)
DOI: 10.1016/j.isci.2026.116862
Score: 9/10 (novelty 3, design 2, population 2, maturity 2)

DARTS proteomics + in vitro/in vivo validation + prospective clinical trial. Dapagliflozin directly binds and partially inhibits GSK3β, mediating podocyte protection. GSK3B rs60393216 polymorphism prospectively associated with UACR reduction after dapagliflozin.
Why it matters: First pharmacogenomic predictor of dapagliflozin renal efficacy — directly applicable to precision nephrology in diabetic kidney disease.

🔴 T1 · Hematologic Malignancies

[HIGH] PMID 42542590 — The requirement of MALT1 activity for the growth of adult T cell leukemia/lymphoma
Kamiunten A, Morishita D, Kameda T et al. | iScience | 2026-07-23 (PMC open)
DOI: 10.1016/j.isci.2026.116850
Score: 9/10 (novelty 3, design 2, population 2, maturity 2)

Selective MALT1 protease inhibitor CRD-1441551 tested across 3 ATL cell lines and 5 patient-derived xenograft models. Sensitivity correlated with constitutive MALT1-NF-κB activation. Partial responses in 5/8 models; strong biomarker rationale for patient selection.
Why it matters: ATL has near-zero long-term survival and no approved targeted therapies. CRD-1441551 is the first MALT1 inhibitor with multi-PDX ATL validation and a clear mechanistic stratification strategy.

🟢 T6 · Novel Therapeutics

[HIGH] PMID 42543223 — JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-activating tri-specific antibody for safe and potent immunotherapy
Gu C, Wang D, Wang Y et al. | MAbs | 2026-08-02
DOI: 10.1080/19420862.2026.2709956
Score: 9/10 (novelty 3, design 2, population 2, maturity 2)

First PD-1-dependent tri-specific antibody combining weak IL-2/15Rβγ nanobody agonism with anti-PD-1 IgG. Cis-activation only in PD-1-high activated T cells. Outperformed parental anti-PD-1 in A375 (melanoma) and NCI-H292 (NSCLC) xenografts. No vascular leak or pulmonary edema in cynomolgus monkeys.
Why it matters: Elegantly solves the IL-2 toxicity vs. efficacy problem for solid tumors; non-human primate safety data de-risk clinical translation of this first-in-class tri-specific.

[HIGH] PMID 42542574 — Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy
Engel A, Vernet R, Charrier E et al. | iScience | 2026-07-24 (PMC open)
DOI: 10.1016/j.isci.2026.116938
Score: 9/10 (novelty 3, design 2, population 2, maturity 2)

Myo-P3: retrievable hollow-fiber device containing engineered myoblasts secreting anti-CTLA-4 locally. Peritumoral implantation in murine colorectal cancer delayed tumor progression, reduced FoxP3+ Tregs, and maintained dramatically lower systemic antibody levels vs. systemic ipilimumab.
Why it matters: Novel controllable, retrievable platform that could unlock anti-CTLA-4 for patients ineligible for systemic ipilimumab due to toxicity; directly addresses the main clinical barrier to CTLA-4 blockade.

🟠 T8 · Aging, Longevity & Population Health

[HIGH] PMID 42542973 — Activation of the Lactate Receptor GPR81 Ameliorates Senescence Hallmarks and Improves Muscle Function in Cellular and Progeroid Models of Aging
Mehrotra P, Bhamidipati SH, Lei P et al. | Aging Cell | 2026-08-01
DOI: 10.1111/acel.70647
Score: 9/10 (novelty 3, design 2, population 2, maturity 2)

GPR81 loss in senescent myoblasts drives lipid accumulation, DNA damage, ROS, and impaired mitochondrial activity. GPR81 agonists rescue lipid oxidation and senescence hallmarks in vitro; significantly improved muscle regeneration in progeric mice.
Why it matters: Novel druggable target for sarcopenia — GPR81 agonists exist and sarcopenia has no approved pharmacotherapy; affects hundreds of millions worldwide.

🔷 Sentinel Scan

[HIGH] PMID 42543473 — Digital patient safety interventions in primary care: a systematic review and meta-analysis
Tsang JY, Planner C, Low CN et al. | BMC Med | 2026-08-03 (OA)
DOI: 10.1186/s12916-026-05048-8
Score: 9/10 (novelty 2, design 2, population 2, maturity 3)

74 RCTs meta-analyzed. Digital interventions improve medication safety (OR 1.46), non-medication process measures (OR 1.77), and adverse events (OR 1.17). Multicomponent CDS + audit-feedback most effective; patient-facing components add for non-medication outcomes.
Why it matters: Largest meta-analysis of digital primary care safety to date; immediately actionable for health systems implementing AI-assisted clinical decision support.

🟡 HIGH PRIORITY — Score 8

Notable detail — PMID 42543381 (STTT): Comprehensive review across 22 cancer types with clinical trial evidence. Covers AI-powered resistance analytics, PDO/PDX models, single-cell omics. High-value reference for precision oncology pipeline contextualization.

Notable detail — PMID 42543083: 42% of 229 adults had discordant IR tissue phenotypes; adipose IR independently drove liver fat, glycemic variability, and cardiometabolic risk while isolated muscle IR was relatively benign. Implications for phenotype-specific therapeutic targeting.

🟡 HIGH PRIORITY — Score 7

⚠️ Flagged safety signal (PMID 42542974): EMA PRAC opened formal assessment June 2026. Six case reports of lithium elevation/toxicity after GLP-1 initiation or escalation. Lithium levels should be monitored when adding or changing GLP-1 agents in patients on lithium. Evidence base weak but regulatory signal is active.

🟤 MEDIUM PRIORITY — Score 6

🟤 MEDIUM PRIORITY — Score 5

⬇️ LOW PRIORITY — Score 4

📊 Coverage Summary

Notable gaps today:

• T2 (CBC + ML): Zero results in 2026-08-03 window — no new hematology analyzer or CBC-ML papers indexed today.
• T3 (Liquid biopsy): Only 1 result returned, confirmed false positive (TCM breast cancer paper matching on abstract terms).
• T9 (Rare diseases): Single result was a PD training RCT, not a rare disease paper; matched on "unmet need" phrase.

Generated: 2026-08-03T09:00:00Z | Attempt 1/3 | Model: anthropic/claude-sonnet-4-6